UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages

Journal of hepatology, 2020-10, Vol.73 (4), p.757-770

2020

Volltextzugriff (PDF)

Myeloid cells in liver and bone marrow acquire a functionally distinct inflammatory phenotype during obesity-related steatohepatitis

Gut, 2020-03, Vol.69 (3), p.551-563

2020

Volltextzugriff (PDF)

Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis

Hepatology (Baltimore, Md.), 2018-04, Vol.67 (4), p.1270-1283

2018

Volltextzugriff (PDF)

Chemokine (C‐C motif) receptor 2–positive monocytes aggravate the early phase of acetaminophen‐induced acute liver injury

Hepatology (Baltimore, Md.), 2016-11, Vol.64 (5), p.1667-1682

2016

Volltextzugriff (PDF)

Differential impact of the dual CCR2/CCR5 inhibitor cenicriviroc on migration of monocyte and lymphocyte subsets in acute liver injury

PloS one, 2017-09, Vol.12 (9), p.e0184694-e0184694

2017

Volltextzugriff (PDF)

Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis

International journal of molecular sciences, 2022-06, Vol.23 (12), p.6696

2022

Volltextzugriff (PDF)

CT-based determination of excessive visceral adipose tissue is associated with an impaired survival in critically ill patients

PloS one, 2021-04, Vol.16 (4), p.e0250321-e0250321

2021

Volltextzugriff (PDF)

The Medium-Chain Fatty Acid Receptor GPR84 Mediates Myeloid Cell Infiltration Promoting Steatohepatitis and Fibrosis

Journal of clinical medicine, 2020-04, Vol.9 (4), p.1140

2020

Volltextzugriff (PDF)

Dissecting Acute Drug‐Induced Hepatotoxicity and Therapeutic Responses of Steatotic Liver Disease Using Primary Mouse Liver and Blood Cells in a Liver‐On‐A‐Chip Model

Advanced science, 2024-08, Vol.11 (30), p.e2403516-n/a

2024

Volltextzugriff (PDF)

Efruxifermin, an investigational treatment for fibrotic or cirrhotic nonalcoholic steatohepatitis (NASH)

Expert opinion on investigational drugs, 2023-06, Vol.32 (6), p.451-461

2023

Volltextzugriff (PDF)

Pharmacotherapeutic options for metabolic dysfunction-associated steatotic liver disease: where are we today?

Expert opinion on pharmacotherapy, 2024-06, Vol.25 (9), p.1249-1263

2024

Volltextzugriff (PDF)

Editorial: prevalence, progression rates and mortality predictors of non‐alcoholic fatty liver disease reflected by German statutory health insurance data

Alimentary pharmacology & therapeutics, 2020-10, Vol.52 (8), p.1412-1413

2020

Volltextzugriff (PDF)

Soluble Urokinase Plasminogen Activator Receptor Levels Are Associated with Severity of Fibrosis in Patients with Primary Sclerosing Cholangitis

Journal of clinical medicine, 2022-04, Vol.11 (9), p.2479

2022

Volltextzugriff (PDF)

Association of Serum Calprotectin Concentrations with Mortality in Critically Ill and Septic Patients

Diagnostics (Basel), 2020-11, Vol.10 (11), p.990

2020

Volltextzugriff (PDF)

Efruxifermin, an investigational treatment for fibrotic or cirrhotic non-alcoholic steatohepatitis (NASH)

Expert opinion on investigational drugs, 2023-06

2023

Volltextzugriff (PDF)

Low Serum Levels of Soluble Receptor Activator of Nuclear Factor κ B Ligand (sRANKL) Are Associated with Metabolic Dysregulation and Predict Long-Term Mortality in Critically Ill Patients

Diagnostics (Basel), 2021-12, Vol.12 (1), p.62

2021

Volltextzugriff (PDF)

THU-291-YI Cellular senescence is a common hallmark in diverse models of steatotic liver diseases

Journal of hepatology, 2024-06, Vol.80, p.S594-S595

2024

Volltextzugriff (PDF)

FRI-457 CXCL12 restricts hepatocellular carcinoma progression by shaping the tumor microenvironment in liver fibrosis

Journal of hepatology, 2024-06, Vol.80, p.S414-S414

2024

Volltextzugriff (PDF)

Acquisition of epithelial plasticity in human chronic liver disease

Nature (London), 2024-05, Vol.630 (8015), p.166-4

2024

Volltextzugriff (PDF)

PS-007-Differential therapeutic effects of pan- and single PPAR agonists on steatosis, inflammation, macrophage composition and fibrosis in a murine model of non-alcoholic steatohepatitis

Journal of hepatology, 2019-04, Vol.70 (1), p.e8-e9

2019

Volltextzugriff (PDF)

AS016 - Combination therapy with a dual CCR2/CCR5 antagonist and a FGF21 analogue synergizes in ameliorating steatohepatitis and fibrosis

Journal of hepatology, 2020-08, Vol.73, p.S13-S13

2020

Volltextzugriff (PDF)

Combination therapy with a dual CCR2/CCR5 antagonist and a FGF21 analogue synergizes in ameliorating steatohepatitis and fibrosis

Journal of hepatology, 2020-08, Vol.73, p.S13

2020

Volltextzugriff (PDF)

Diagnostik und Therapie der schweren akuten Pankreatitis in der Intensivmedizin

Deutsche medizinische Wochenschrift, 2020-06, Vol.145 (12), p.850-862

2020

Volltextzugriff (PDF)

Die nichtalkoholische Steatohepatitis (NASH) als Ursache erhöhter Leberwerte

Deutsche medizinische Wochenschrift, 2023-06, Vol.148 (13), p.818-827

2023

Volltextzugriff (PDF)

1 – 24 von 24

Suche als RSS-Feed

Aktive Filter

ThemaHumans

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(24)
Mit Volltextzugriff
(17)

Publikationsform

Artikel
(24)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages

Myeloid cells in liver and bone marrow acquire a functionally distinct inflammatory phenotype during obesity-related steatohepatitis

Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis

Chemokine (C‐C motif) receptor 2–positive monocytes aggravate the early phase of acetaminophen‐induced acute liver injury

Differential impact of the dual CCR2/CCR5 inhibitor cenicriviroc on migration of monocyte and lymphocyte subsets in acute liver injury

Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis

CT-based determination of excessive visceral adipose tissue is associated with an impaired survival in critically ill patients

The Medium-Chain Fatty Acid Receptor GPR84 Mediates Myeloid Cell Infiltration Promoting Steatohepatitis and Fibrosis

Dissecting Acute Drug‐Induced Hepatotoxicity and Therapeutic Responses of Steatotic Liver Disease Using Primary Mouse Liver and Blood Cells in a Liver‐On‐A‐Chip Model

Efruxifermin, an investigational treatment for fibrotic or cirrhotic nonalcoholic steatohepatitis (NASH)

Pharmacotherapeutic options for metabolic dysfunction-associated steatotic liver disease: where are we today?

Editorial: prevalence, progression rates and mortality predictors of non‐alcoholic fatty liver disease reflected by German statutory health insurance data

Soluble Urokinase Plasminogen Activator Receptor Levels Are Associated with Severity of Fibrosis in Patients with Primary Sclerosing Cholangitis

Association of Serum Calprotectin Concentrations with Mortality in Critically Ill and Septic Patients

Efruxifermin, an investigational treatment for fibrotic or cirrhotic non-alcoholic steatohepatitis (NASH)

Low Serum Levels of Soluble Receptor Activator of Nuclear Factor κ B Ligand (sRANKL) Are Associated with Metabolic Dysregulation and Predict Long-Term Mortality in Critically Ill Patients

THU-291-YI Cellular senescence is a common hallmark in diverse models of steatotic liver diseases

FRI-457 CXCL12 restricts hepatocellular carcinoma progression by shaping the tumor microenvironment in liver fibrosis

Acquisition of epithelial plasticity in human chronic liver disease

PS-007-Differential therapeutic effects of pan- and single PPAR agonists on steatosis, inflammation, macrophage composition and fibrosis in a murine model of non-alcoholic steatohepatitis

AS016 - Combination therapy with a dual CCR2/CCR5 antagonist and a FGF21 analogue synergizes in ameliorating steatohepatitis and fibrosis

Combination therapy with a dual CCR2/CCR5 antagonist and a FGF21 analogue synergizes in ameliorating steatohepatitis and fibrosis

Diagnostik und Therapie der schweren akuten Pankreatitis in der Intensivmedizin

Die nichtalkoholische Steatohepatitis (NASH) als Ursache erhöhter Leberwerte

Aktive Filter

Suchergebnisse filtern